As a new-type foreign trade service provider driven by technological transformation and foreign trade services, HiSiaddi has established a service system of "1+2+3+4=1" and can supply PVP from multiple well-known original manufacturers.
Endowed with R&D capabilities, HiSiaddi has long collaborated with factories on technology commercialization and accurately captured market demands, repeatedly proposing PVP formulation optimization schemes and application improvement recommendations. Below is a case study of HiSiaddi’s PVP formulation optimization consulting service.
Contact HiSiaddi customer service for more formulation optimization consulting inquiries.
MediCare, a long-established European formulation R&D enterprise headquartered in Milan, Italy, historically sourced pharmaceutical-grade PVP from BASF imports. To compress supply chain costs and shorten lead times, the group selected two domestic manufacturers for customized production of three dedicated PVP grades. After raw materials arrived and were put into formulation production lines, three major mass production failures occurred consecutively: abnormal tablet disintegration, white precipitate in injections under low-temperature storage, and cracking & peeling of medical beauty wound gels. Around 1,400kg of semi-finished products under production faced scrapping, and new drug registration applications were suspended for 42 days.
Raw material manufacturers only guaranteed factory-test K values and moisture content, taking responsibility solely for off-site raw material indicators and refusing to troubleshoot hidden risks combined with downstream formulation processes. After failures emerged, they unilaterally attributed defects to unreasonable client formulation processes, leading to a deadlock in root cause identification. The client’s formulation engineers lacked familiarity with characteristics of domestic PVP including monomer residues, molecular weight distribution and powder microstructures, and made no progress in independent rectification. The group entrusted technology-focused foreign trade firm HiSiaddi to conduct full-process technical diagnosis, raw material modification, formulation optimization and standardized mass production process implementation.
The client adopted this PVP grade as a matrix binder for long-acting sustained-release tablets with internal control standard: 75%±5% drug release within 12 hours via in-vitro dissolution testing. Actual mass-produced samples only released 49% of the drug within 12 hours, with extremely slow disintegration in simulated gastric fluid. Root Cause: Although the average K value of domestic PVP met standards, its overly broad molecular weight distribution contained a high proportion of high-molecular fragments, which formed a dense hydrophobic gel layer upon contact with gastric fluid and hindered drug dissolution. Meanwhile, trace residual NVP monomers altered the material’s hydrophilic-lipophilic balance and disrupted the original sustained-release formulation ratio. Original BASF PVP featured molecular weight distribution width <1.2, while the original domestic batch recorded distribution width >2.6.
PVP was used as a solubilizer for oral liquids and sterile injections. Samples remained clear at room temperature but formed fine flocculent precipitates after 15 days of storage at 5℃, failing EU sterile formulation stability testing. Root Cause: Insufficient refining depth led to excessive 2-pyrrolidone residues and high levels of low-molecular oligomer fragments, which precipitated and agglomerated under low-temperature conditions. Imported injection-grade PVP undergoes multi-stage devolatilization to rigorously remove small-molecule impurities.
Water-based wound gels coated with the PVP grade shrank and cracked after 72 hours at room temperature, failing to adhere tightly to wound skin. Root Cause: Chaotic particle size distribution of customized powder mixed excessive fine dust and oversized particles, creating uneven internal structures after film formation. Trace residual aldehyde impurities in PVP cross-linked with collagen in the formulation and increased film brittleness.
The client retained the feeding process designed for imported raw materials, adding PVP powder to aqueous phase heated to 80℃. High temperature triggered partial degradation of PVP, reduced molecular weight and drastically weakened gel film-forming strength.
HiSiaddi deployed pharmaceutical polymer engineers and formulation engineers to coordinate raw material polymerization & refining process upgrades with upstream manufacturers, while optimizing end-product formulations and workshop SOPs for the Italian client.
1. Raw Material End Process Rectification: Coordinated manufacturers to rework polymerization processes with segmented temperature control and gradient dropwise addition of NVP monomers, narrowing molecular weight distribution width to ≤1.3. An ultrafiltration classification process was added to eliminate ultra-high-molecular polymer fragments, and NVP monomer residues were strictly controlled below 10ppm.
2. Client Formulation Fine-Tuning: Slightly adjusted the ratio of microcrystalline cellulose and lactose in the original formula, with a small amount of low-substituted hydroxypropyl cellulose to buffer matrix hydrophilicity, without changing the main drug dosage.
3. Dissolution Verification: After rectification, in-vitro sustained-release dissolution curves returned to standard ranges, with 73.8% drug release at 12 hours, complying with internal pharmacopoeia controls.
1. Manufacturer Refining Upgrade: Added thin-film evaporation and ion exchange resin impurity removal processes on top of original vacuum devolatilization, controlling 2-pyrrolidone ≤0.11% and removing over 92% of low-molecular oligomers.
2. Client Formulation Optimization: Fine-tuned the pH value of injection buffer salts to 5.2~5.6 to reduce precipitation tendency of small-molecule fractions under low temperature.
3. Stability Testing: Liquid remained clear with zero precipitates after 90 days of constant-temperature storage at 5℃.
1. Raw Material Modification: Manufacturers optimized spray drying parameters and air classification sieving to remove excess fine dust and oversized particles, retaining standard powder with D50 around 30μm. Activated carbon adsorption was applied to eliminate aldehyde impurities.
2. Formulation Optimization: A small amount of medical glycerin was added as a plasticizer (compliant with EU organic excipient specifications) to boost film flexibility and avoid shrinkage cracking during drying.
1. Mandatory Rules: PVP powder shall be added under low-speed stirring only after the feed liquid cools below 45℃; complete pre-dissolution at room temperature before heating for homogenization.
2. Raw materials shall be stored in workshops away from light and moisture; opened PVP stock must be fully consumed within 48 hours. HiSiaddi issued bilingual operation manuals in Italian and English and provided remote training for production teams.
1. Cross-Border Sample Testing: Rectified PVP samples of all three grades were air-shipped to Milan R&D laboratories; full compatibility, stability and pharmacopoeia index tests fully matched original BASF raw materials.
2. Medium-Scale Implementation: 550kg medium-scale batches were produced for each grade, and the client conducted small-batch full-line production. After 3 months of retained sample observation and third-party testing by Italian pharmaceutical authorities, all products met standards.
3. Batch Shipment of Orders: A total of 11.8 tons of goods were shipped in seven consignments from Shanghai Port to Genoa Port with smooth customs clearance and no inspections.
1. 1,400kg of unqualified semi-finished products were reworked and reused via formulation fine-tuning, eliminating approximately 112,000 Euros in scrapping losses. The three formulations successfully passed EMA registration filings and launched on Italian hospital channels on schedule. Overall procurement cost of domestic raw materials fell by 33.1% versus BASF imports.
2. A 13.5-ton annual long-term order was renewed the following year, with additional customized procurement requests for crospovidone and PVP-VA copolymers.
Leveraging this European pharmaceutical rectification case, manufacturers standardized three production processes: narrow K-value classification, deep impurity removal for injection-grade products and customized particle size control. High-end pharmaceutical grades achieved a 29% export premium, and the case supported expansion of orders from pharmaceutical enterprises in Switzerland and Spain, escaping low-price competition for industrial-grade PVP.
HiSiaddi built a failure diagnosis database for pharmaceutical-grade PVP formulations and formed a complete technical service system covering upstream raw material polymerization optimization, downstream formulation adjustment and mass production process guidance. It continued to undertake PVP technical supporting projects for pharmaceutical enterprises across Europe.
1. Pain Points of High-End Overseas Pharmaceutical Enterprises: European and American pharmaceutical companies have long used finely graded BASF PVP and lack familiarity with drawbacks of domestic PVP including broad molecular weight distribution and insufficient control of trace impurities. Direct replication of original mature formulas easily causes formulation failures. Domestic raw material manufacturers only monitor factory physical and chemical indicators and lack research on downstream formulation applications, making them unable to predict hidden formulation risks.
2. Core Technical Highlights of Products: Molecular weight distribution, residual monomers, powder particle size and trace impurities of PVP are four key indicators affecting three core application scenarios: tablet sustained release, injection stability and gel film formation. Pharmaceutical-grade PVP cannot adopt polymerization and drying processes designed for general industrial grades.
3. Core Value of HiSiaddi: As a neutral third party, HiSiaddi bridges information gaps between raw material manufacturers and formulation end-users, conducting simultaneous rectification across three dimensions: upstream raw material technical upgrades, downstream formulation optimization and on-site production standardization, balancing manufacturers’ production costs and pharmaceutical enterprises’ formulation usage requirements.
Contact HiSiaddi customer service for more formulation optimization consulting inquiries.
+86-13120989737 
info@hisiaddi.com 
English
